Evaluation of Sulfasalazine as an Adjunctive Therapy in Treating Pulmonary Pre-XDR-TB: Efficacy, Safety, and Treatment Implication.

Liang FuWenfei WangJuan Xiong Peize Zhang Hui LiXilin ZhangHancheng LiangQianting YangZhaoqin WangXinchun ChenGuofang DengYi CaiShenjie Tang

Published in: Infection and drug resistance (2024)

Both 9-month short-course, all-oral regimens manifested commendable primary efficacy in treating pre-XDR-TB patients. The SASP-regimen emerged as effective, safe, well-tolerated, and cost-effective.

Keyphrases

end stage renal disease
drug resistant
mycobacterium tuberculosis
ejection fraction
chronic kidney disease
newly diagnosed
pulmonary hypertension
prognostic factors
peritoneal dialysis
stem cells
patient reported outcomes
multidrug resistant
mesenchymal stem cells
replacement therapy
patient reported